Use a Low-Molecular-Weight Heparin for Most Patients With Cancer-Associated VTE

We're getting questions about whether to use a direct oral anticoagulant (DOAC) in patients with cancer-associated thromboembolism.

The role of DOACs (Eliquis, Xarelto, etc) is expanding. Chest guidelines now favor these meds for most patients with venous thromboembolism (VTE)...deep vein thrombosis or pulmonary embolism.

But don't recommend jumping to a DOAC first-line to treat or prevent recurrent VTE in patients with cancer. There's limited evidence about the efficacy and safety of DOACs in this case.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote